Xin Lang Ji Jin·2026-02-26 07:04Group 1 - The core viewpoint of the article highlights a significant decline in Hong Kong pharmaceutical stocks, particularly in the innovative drug sector, with the Hong Kong Stock Connect Innovative Drug ETF (520880) and the Hong Kong Stock Connect Medical ETF (159137) both dropping over 2% [1][2] - The leading company, BeiGene, experienced a drop of over 6% and is set to disclose its 2025 financial report today. It holds significant weight in the aforementioned ETFs, accounting for 11.27% and 2.13% of their respective portfolios [2] - According to Kaiyuan Securities, the Chinese innovative drug sector is transitioning from "scale accumulation" to "value release," indicating a shift from pipeline expectations to performance realization. The innovative drug sector has seen a two-quarter correction, but many quality stocks are now considered to have attractive valuations, suggesting increased attention is warranted [2] Group 2 - The article suggests that investors should consider low-positioned opportunities in Hong Kong pharmaceutical stocks through ETFs for higher efficiency and flexibility, particularly recommending the Hong Kong Stock Connect Innovative Drug ETF (520880) and its associated funds [2] - The Hong Kong Stock Connect Medical ETF (159137) is recommended for its focus on medical innovation, covering hot concepts such as brain-computer interfaces, AI healthcare, and internet pharmacies, while also encompassing leading companies across the entire innovative drug supply chain [2]